Chimerix (CMRX) Lowered to “Underweight” at JPMorgan Chase & Co.

Chimerix (NASDAQ:CMRX) was downgraded by JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research note issued to investors on Wednesday, Marketbeat.com reports.

Several other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Chimerix from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. ValuEngine lowered shares of Chimerix from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th. Finally, HC Wainwright assumed coverage on shares of Chimerix in a report on Friday, February 2nd. They issued a “buy” rating and a $10.00 target price on the stock. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $7.06.

Chimerix (NASDAQ CMRX) remained flat at $$4.93 on Wednesday. The stock had a trading volume of 434,825 shares, compared to its average volume of 276,791. The stock has a market capitalization of $229.98, a price-to-earnings ratio of -3.45 and a beta of 1.42. Chimerix has a 1-year low of $4.17 and a 1-year high of $6.64.

In other Chimerix news, insider Linda M. Richardson sold 19,833 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.40% of the company’s stock.

Several hedge funds have recently modified their holdings of CMRX. Prosight Management LP acquired a new position in shares of Chimerix in the 4th quarter worth approximately $6,846,000. ArrowMark Colorado Holdings LLC lifted its holdings in shares of Chimerix by 58.3% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,707,986 shares of the biopharmaceutical company’s stock worth $12,538,000 after acquiring an additional 996,936 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Chimerix by 20.7% in the 4th quarter. BlackRock Inc. now owns 3,530,729 shares of the biopharmaceutical company’s stock worth $16,348,000 after acquiring an additional 605,075 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Chimerix by 38.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,448,250 shares of the biopharmaceutical company’s stock worth $7,893,000 after acquiring an additional 404,914 shares during the last quarter. Finally, Ascend Capital LLC lifted its holdings in shares of Chimerix by 96.9% in the 4th quarter. Ascend Capital LLC now owns 699,664 shares of the biopharmaceutical company’s stock worth $3,240,000 after acquiring an additional 344,311 shares during the last quarter. Hedge funds and other institutional investors own 70.33% of the company’s stock.

WARNING: “Chimerix (CMRX) Lowered to “Underweight” at JPMorgan Chase & Co.” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/14/chimerix-cmrx-lowered-to-underweight-at-jpmorgan-chase-co.html.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply